# US 11,304,969 B2 · Treatments of prostate cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,969 B2
- Document ID: US11304969B2
- Status: Granted
- Kind: B2
- Application number: 16/751,696
- Filed: 2020-01-24
- Published: 2021-07-29
- Granted: 2022-04-19
- Earliest claimed: 2020-01-24
- Assignees: The Florida International Univeristy Board of Trustees
- Applicants: Yuk-Ching Tse-Dinh; Yuan Liu; Irina Agoulnik
- Inventors: Yuk-Ching Tse-Dinh; Yuan Liu; Irina Agoulnik
- Web page: https://patentgrep.com/patent/US11304969B2

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 35/00: Antineoplastic agents
- A61K 31/4365: the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides compounds, compositions and methods for the treatment of prostate cancers, preferably, advanced prostate cancers. The subject invention also provides compounds, compositions and methods for preventing/slowing down/reducing the progress and proliferation of prostate cancer cells. The subject invention further provides compounds, compositions and methods for inhibiting DNA repair within cancer cells to slow tumor growth, preferably, by inhibiting BER capacity, including pol β and LIG I.

## Claims

### Claim 1

A method for treating prostate cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising one or more compounds selected from natamycin, ceftazidime, nystatin and prasugrel.

### Claim 2 (depends on 1)

The method of claim 1, the prostate cancer being organ-confined primary prostate cancer, locally invasive advanced prostate cancer, metastatic prostate cancer, or castration-resistant prostate cancer (CRPC).

### Claim 3 (depends on 2)

The method of claim 2, the prostate cancer being CRPC.

### Claim 4 (depends on 1)

The method of claim 1, the composition comprising at least natamycin.

### Claim 5 (depends on 1)

The method of claim 1, the administration being local, oral, transdermal, parenteral, intracranial, intracerebral, intraspinal, intrauterine, or rectal administration.

### Claim 6 (depends on 1)

The method of claim 1, the composition further comprising an antiandrogen agent.

### Claim 7 (depends on 1)

The method of claim 1, the treatment of prostate cancer being through the inhibition of base excision repair (BER).

### Claim 8

A method for inhibiting/slowing down the progress and proliferation of prostate cancer cells comprising administering to a subject in need an effective amount of a pharmaceutical composition comprising one or more compounds selected from natamycin, ceftazidime, nystatin and prasugrel.

### Claim 9 (depends on 8)

The method of claim 8, the prostate cancer being organ-confined primary prostate cancer, locally invasive advanced prostate cancer, metastatic prostate cancer, or CRPC.

### Claim 10 (depends on 9)

The method of claim 9, the prostate cancer being CRPC.

### Claim 11 (depends on 8)

The method of claim 8, the composition comprising at least natamycin.

### Claim 12 (depends on 8)

The method of claim 8, the administration being local, oral, transdermal, parenteral, intracranial, intracerebral, intraspinal, intrauterine, or rectal administration.

### Claim 13 (depends on 8)

The method of claim 8, the composition further comprising an antiandrogen agent.

### Claim 14 (depends on 1)

The method of claim 1, the pharmaceutical composition further comprising one or more compounds selected from sirolimus, flecainide acetate, dihydroergotamine mesylate, risperidone, dipyridamole, doxycycline monohydrate, methylergonovine maleate, paliperidone, reserpine, and sunitinib malate.

### Claim 15 (depends on 8)

The method of claim 8, the pharmaceutical composition further comprising one or more compounds selected from sirolimus, flecainide acetate, dihydroergotamine mesylate, risperidone, dipyridamole, doxycycline monohydrate, methylergonovine maleate, paliperidone, reserpine, and sunitinib malate.